Seeking Alpha

Galectin gets fast-track designation for fatty liver disease drug

  • The FDA grants fast-track designation to Galectin Therapeutics' (GALT) GR-MD-O2 treatment for treating non-alcoholic steatohepatitis (NASH) with hepatic fibrosis, commonly known as fatty liver disease with advanced fibrosis. It's a condition associated with obesity and affects 9-15M people in the U.S., including children.
  • GR-MD-O2 is in Phase I trials
  • "Our preclinical data has shown that GR-MD-02 has robust treatment effects in reversing fibrosis and cirrhosis," says CEO Peter Traber. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector